Principal Investigator: Thierry Dervieux, CSO and Laboratory director, Prometheus Laboratories
Specific Aim:
- The specific aim to establish the association between ADA PK and clinical outcome and disease control from the
Improve Care now data registry. Our hypothesis is that higher Clearance and lower exposure associate with worse
clinical outcomes in pediatric IBD patients receiving ADA, thus delineating a subpopulation of patients that will
benefit from dose intensification.
Study Period: November 2024
Contact: Thierry Dervieux